Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin

Stroke

Volumn 34, Issue 1, 2003, Pages 234-235

  Algra, A ^a   De Schryver, E L L M ^b   Van Gijn, J ^b   Kappelle, L J ^b   Koudstaal, P J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

Anticoagulants; Antiplatelet therapy; Cerebral ischemia; Randomized controlled trials

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PHENPROCOUMON; WARFARIN;

BLEEDING; DRUG SAFETY; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; SHORT SURVEY; STROKE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CEREBRAL ARTERIES; CEREBROVASCULAR ACCIDENT; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037224704     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000047035.04395.ED     Document Type: Short Survey

References (13)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
2. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1996;60:197-199.
3. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;66:255. Letter.
4. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 1980;2:989-994.
5. Smith P, Amesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147-152.
6. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 1994;343:499-503.
7. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med. 1982;307:701-708.
8. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857-865.
9. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjeme LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke. 1983;14:677-681.
10. Olsson JE, Brechter C, Backlund H, Krook H, Muller R, Nitelius E, Olsson O, Tornberg A. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke. 1980;11:4-9.
11. Stewart B, Shuaib A, Veloso F, for the SWAT Investigators. Stroke prevention with warfarin or aspirin trial (SWAT). Stroke. 1998;29:304. Abstract.
12. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
13. Tom M, Algra A, Rosendaal FR. Oral anticoaguladon for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology. 2001;57:1993-1999.